Pharmaceutical company Adcock Ingram has advised shareholders that its earnings per share (EPS) and headline earnings per share (HEPS) for the six months ended December 31, were expected to show an improvement of between 27% and 30%, or between 50.4c and 56c, year-on-year. This compares with the EPS and HEPS of 186.5c reported for the six-month period to December 31, 2020. Adcock expects to publish its interim results on February 23. The company said that, at the time of the publication of this statement, it did not have reasonable certainty of its earnings that would enable it to provide more specific guidance on the range of EPS or HEPS.